Great Diversity Found at Rutgers University

Joshua J. Neumiller, PharmD, CDCES, of the American Diabetes Association, discusses pharmacists’ role in diabetes and CKD care at ASN Kidney Week 2026.

Jai Radhakrishnan, MD, MBBS, MS, FASN, discusses why IgG4-related kidney disease is often missed and what the MITIGATE subgroup data presented at ASN Kidney Week 2026 show.

The provider-administered IL-23 inhibitor improved ACR20 response vs placebo after 2 doses in the phase 3 INSPIRE-1 and INSPIRE-2 trials.

Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.

Treated patients also had fewer post-acute hospitalizations and deaths, but individuals without risk factors saw no benefit.

A pharmacy technician reflects on 3 patient encounters that reshaped his understanding of what a real patient requires.

In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg per day was linked to more kidney failure and higher all-cause mortality.

A disease-modifying therapy for stage 3 T1D, a second once-weekly insulin, and automated insulin delivery for T2D mark a busy year in diabetes care.